Anavex Life Sciences Corp (AVXL)

[chrismiss_everyday]

In the United States...

We estimated a total of 1.04 million individuals with diagnosed PD in the U.S. in 2017 with an associated $51.9 billion in total economic costs. We estimated direct medical costs of $25.4 billion and indirect and non-medical costs of $26.5 billion.Jul 9, 2020

According to recent estimates from the Alzheimer's Association, the total direct medical expenditures associated with ADRD in the United States will increase from $236 billion in 2016 to more than $1 trillion in 2050 due to projected increases in the elderly population [2].Apr 1, 2018

We found an estimated half million increase in MS admissions, annually, which was projected to exceed 43.5 million by the end of year 2017. We also found the charge and the costs associated with MS care increased at rates of US$ 40 million a year and US$ 8 million a year, respectively.Jul 1, 2017

https://www.nature.com/scitable/topicpage/protein-misfolding-and-degenerative-diseases-14434929/

Anavex 2-73 is an oral small molecule designed to activate the protein sigma-1 receptor (S1R), which is involved in proper protein folding. By reducing the toxic accumulation of misfolded proteins in nerve cells, Anavex 2-73 is believed to reduce inflammation and cellular stressors in the brain.

The potential is staggering and positive. (And 3-71 is only getting started.)